Details of Drug-Drug Interaction
| Drug General Information (ID: DDIP3Q9K7F) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Pyridoxine | Drug Info | Levodopa | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Vitamins | Dopaminergic Antiparkinsonism Agents | |||||||
| Structure | |||||||||
| Mechanism of Pyridoxine-Levodopa Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of dopaminergic agents Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Pyridoxine | Levodopa | |||||||
| Mechanism |
Antidopaminergic effects Increase peripheral metabolism of levodopa |
Dopaminergic agent Dopamine receptor Agonist |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Dopamine receptor | Structure Sequence | |||||||
| Protein Family | G-protein coupled receptor 1 family | ||||||||
| Protein Function |
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | The concomitant use of pyridoxine and levodopa without dopa-decarboxylase inhibitors should be avoided. Patients should be advised against taking pyridoxine-containing vitamin supplements. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||||||||||||||||
| 2 | Product Information. Diclectin (doxylamine-pyridoxine). Duchesnay Inc, Laval, IN. | ||||||||||||||||||

